Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-11-28, Stock:ABBV, The news for the past five days is as follows:
2018-11-20: NEWS1: AbbVie (ABBV) Stock Moves -1.55%: What You Should Know.NEWS2: 3 Top Large-Cap Stocks to Buy in November.NEWS3: 3 Top Large-Cap Stocks to Buy in November.NEWS4: 3 Top Large-Cap Stocks to Buy in November.NEWS5: Why Has AstraZeneca’s Stock Price Increased in 2018?.NEWS6: SHAREHOLDER ALERT: ABBV JT CWH HON DY RYAAY: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines.NEWS7: DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against AbbVie Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm.NEWS8: FINAL DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against AbbVie Inc. (ABBV) & Lead Plaintiff Deadline - November 20, 2018.NEWS9: AbbVie to Highlight Breadth of Innovative Science and Ongoing Commitment to Blood Cancer Patients with New Data From Studies of Ibrutinib and Venetoclax at 2018 American Society of Hematology Annual Meeting & Exposition.NEWS10: Today's Research Reports on Trending Tickers: AstraZeneca and AbbVie.
2018-11-21: NEWS1: AbbVie (ABBV) Shares Cross 5% Yield Mark.NEWS2: AbbVie (ABBV) Shares Cross 5% Yield Mark.NEWS3: AbbVie Receives US FDA Accelerated Approval for VENCLEXTA® (venetoclax) for Treatment of Newly-Diagnosed Acute Myeloid Leukemia Patients Ineligible for Intensive Chemotherapy.NEWS4: The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of ABBV, MGTI, ACHC, JT and HTHT.NEWS5: AbbVie (ABBV) Stock Moves -1.55%: What You Should Know.NEWS6: AbbVie (ABBV) Stock Moves -1.55%: What You Should Know.
2018-11-23: NEWS1: FDA Approves Roche Subsidiary's Treatment for Acute Myeloid Leukemia.NEWS2: Pharma Stock Roundup: Cancer Approvals for PFE & ABBV, CHMP Nod for Several Drugs.NEWS3: Pharma Stock Roundup: Cancer Approvals for PFE & ABBV, CHMP Nod for Several Drugs.NEWS4: Gauging Analysts’ Views on Tesaro Stock.NEWS5: Understanding Tesaro’s Gross Margin Trend.NEWS6: Pharma Stock Roundup: Cancer Approvals for PFE & ABBV, CHMP Nod for Several Drugs.
2018-11-26: NEWS1: The Zacks Analyst Blog Highlights: Pfizer, AbbVie, J&J, Glaxo and AstraZeneca.NEWS2: The Zacks Analyst Blog Highlights: Pfizer, AbbVie, J&J, Glaxo and AstraZeneca.NEWS3: 2 Dividend Stocks You'll Wish You'd Bought 32 Years From Now.NEWS4: 2 Dividend Stocks You'll Wish You'd Bought 32 Years From Now.NEWS5: Gilead's HIV Franchise, CAR T Therapy Likely to Propel Growth.NEWS6: Gilead's HIV Franchise, CAR T Therapy Likely to Propel Growth.NEWS7: 2 Dividend Stocks You&apos;ll Wish You&apos;d Bought 32 Years From Now.NEWS8: The Zacks Analyst Blog Highlights: Pfizer, AbbVie, J&J, Glaxo and AstraZeneca.NEWS9: Gilead's HIV Franchise, CAR T Therapy Likely to Propel Growth.NEWS10: 2 Cheap Dividend Stocks You Can Buy Right Now.NEWS11: 2 Cheap Dividend Stocks You Can Buy Right Now.
2018-11-27: NEWS1: 5 Biotech Stocks to Scoop Up for Big Dividends.NEWS2: 5 Biotech Stocks to Scoop Up for Big Dividends.NEWS3: Wall Street Wants the Best Patents, Not the Best Drugs.NEWS4: Enanta Pharmaceuticals Inc (ENTA) Q4 2018 Earnings Conference Call Transcript.

Answer: Rise